USOO9492681 B2 (12) United States Patent (10) Patent No.: US 9,492,681 B2 Aydt et al. (45) Date of Patent: Nov. 15, 2016 (54) DEVICE AND METHOD FOR TREATMENT (2013.01); A61N 2005/0656 (2013.01); A61N OF CELLS AND CELL TISSUE 2005/0659 (2013.01); A61N 2005/0661 (2013.01); A61N 2005/0662 (2013.01); HOIL (75) Inventors: Ewald Aydt, Rossdorf (DE); Herwig 51/502 (2013.01); HOIL 5 1/5032 (2013.01) Buchholz, Frankfurt am Main (DE); (58) Field of Classification Search Junyou Pan, Frankfurt am Main (DE) CPC ................... A61N 2005/0652: A61N 5/0616: A61N 5/062 (73) Assignee: Merck Patent GmbH, Darmstadt (DE) USPC ........................................ 607/88, 89: 604/20 (*) Notice: Subject to any disclaimer, the term of this See application file for complete search history. patent is extended or adjusted under 35 U.S.C. 154(b) by 432 days. (56) References Cited (21) Appl. No.: 13/985,209 U.S. PATENT DOCUMENTS 2005/O1491.50 A1* 7/2005 McDaniel ............ A61N 5,0616 (22) PCT Fed: Jan. 16, 2012 607/88 2010.013795.0 A1 6, 2010 McDaniel (86) PCT No.: PCT/EP2012/OOO156 (Continued) S 371 (c)(1), (2), (4) Date: Aug. 13, 2013 FOREIGN PATENT DOCUMENTS JP 2007-518452. A 7/2007 (87) PCT Pub. No.: WO2O12A1101.78 WO WO-2010/078581 A1 T 2010 PCT Pub. Date: Aug. 23, 2012 (Continued) Prior Publication Data (65) OTHER PUBLICATIONS US 2013/0324909 A1 Dec. 5, 2013 International Preliminary Report on Patentability for PCT/EP2012/ (30) Foreign Application Priority Data 000156, Aug. 21, 2013. International Search Report for PCT/EP2012/000156 mailed Mar. Feb. 14, 2011 (EP) ..................................... 11 OO1174. 22, 2012. (51) Int. C. Primary Examiner — William Thomson A61N L/00 (2006.01) Assistant Examiner — Jeffrey Lipitz A6IN 5/06 (2006.01) (74) Attorney, Agent, or Firm — Drinker Biddle & Reath A6DF 9/008 (2006.01) LLP HOIL 5L/50 (2006.01) (52) U.S. C. (57) ABSTRACT CPC ............. A61N 5/06 (2013.01); A61F 9/00834 The present invention relates to a cells and cell tissue (2013.01); A61N 5/062 (2013.01); A61N treatment device and use thereof. 5/0616 (2013.01); HOIL 51/50 (2013.01); A61N 2005/0653 (2013.01); A61N 2005/0654 18 Claims, 5 Drawing Sheets Al Cathode El Composition PEDOT:PSS TO anode Substrate US 9,492,681 B2 Page 2 (56) References Cited FOREIGN PATENT DOCUMENTS U.S. PATENT DOCUMENTS WO WO-2011,069590 A1 6, 2011 WO WO-2011110275 A2 9, 2011 2010/0179469 A1* 7, 2010 Hammond ........... A61N 5,0603 604/20 2010/0234792 A1 9/2010 Dacey, Jr. et al. * cited by examiner U.S. Patent Nov. 15, 2016 Sheet 1 of 5 US 9,492,681 B2 Figure 1 a Al Cathode EL Composition PEDOT:PSS TO anode Substrate Figure 1b Substrate Figure 1C - - - - - - - - 106 - - - - - - - - 105 - - - - - - - - - - 104 - - - - - - - - - - 103 - - - - - - - - - - 102 - - - - - - - - - - 101 Figure 2 Substrate Coating EML Buffer layer - r. -- - - - Interlayer Cathod 2:3: -drE. en 3. 3. Cap TO 3 Contact pad 1 Contact pad2 U.S. Patent NOV. 15, 2016 sheet 2 of us 9492,681 B. Figure 3 U.S. Patent Nov. 15, 2016 Sheet 3 of 5 US 9,492,681 B2 Fig. 4 U.S. Patent Nov. 15, 2016 Sheet 4 of 5 US 9,492,681 B2 Fig. 5 U.S. Patent Nov. 15, 2016 Sheet S of 5 US 9,492,681 B2 Fig. 6 US 9,492,681 B2 1. 2 DEVICE AND METHOD FOR TREATMENT the body which is to be treated. That area is then exposed to OF CELLS AND CELLTISSUE light of a Suitable frequency and intensity to activate the photopharmaceutical. A variety of photopharmaceutical CROSS-REFERENCE TO RELATED agents are currently available. For example there are topical APPLICATIONS agents such as 5-aminolevulinic acid hydrochloride (Craw ford Pharmaceuticals), methylaminolevulinic acid (Met This application is a national stage application (under 35 fix(R), Photocure). There are also injectable drugs used pri U.S.C. S371) of PCT/EP2012/000156, filed Jan. 16, 2012, marily for internal malignancies, including Photofin R (from which claims benefit of European application 11001174.9, AXcan) and Foscan R (from Biolitech Ltd). Often, the drug filed Feb. 14, 2011. 10 is applied in a non-active form that is metabolized to a The present invention relates to a cells and/or cell tissue light-sensitive photopharmaceutical. treatment device, to a kit of parts for treatment of cells In photodynamic therapy, the primary technique for Sup and/or cell tissue, to use of Such a device or kit of parts and plying light to the photopharmaceutical is to project light of to a method for treatment of cells and cell tissue. a suitable wavelength from standalone light sources such as Phototherapy (also called light therapy) can be employed 15 lasers or filtered arc lamps. These sources are cumbersome in a wide range of therapeutic diseases and/or cosmetic (also and expensive, and are therefore only Suitable for use in called aesthetic) conditions. Phototherapy by either employ hospitals. This leads to inconvenience for the patient, and ing LED or laser as light source has already been used to high cost for the treatment. High light irradiances are needed treat wounds, injuries, neck pain, osteoarthritis, the side in order to treat an acceptable number of patients per day effects of chemotherapy and radiotherapy, for instance. (for the treatment to be cost effective) and to avoid unduly The treatment or prophylaxis of acne may have both inconveniencing the patient. therapeutic and cosmetic components, depending on the To date, phototherapy and PDT is dominated by the degree of the condition. The same accounts for psoriasis, application of large light sources being uncomfortable for atopic dermatitis and other diseases and/or conditions. Many patients leading to low compliance. Many of the devices diseases and conditions are associated with apparent impli 25 which are currently in use are only applicable stationary and cations which are often represented by a change in the require the control of medical professionals, e.g. in hospital visibility of a subject’s skin, for instance. These cosmetic or or in doctor's Surgery. Furthermore, many of the light aesthetic changes can often lead to psychological modifica Sources currently used irradiate large areas of the Subject to tions resulting, at least in part, in serious diseases. be treated, even if only a fraction of it should have been Some conditions or diseases may have an emphasis on 30 irradiated which may lead to unwanted side effects. cosmetic components. Some of these are selected from WO 98/46130 and U.S. Pat. No. 6,096,066 disclose arrays anti-ageing, anti-wrinkle, the prevention and/or therapy of of LEDs for use in photodynamic therapy. The small LED acne and vitiligo. Sometimes, therapeutic elements may also Sources taught therein result in uneven light incident on the play a role. patient. Fabrication of arrays is complicated because of the In both cosmetics and medicine the skin is the main target 35 large number of connections required. The devices shown to be irradiated, but other targets of the human or animal therein are designed for hospital treatment. body can also be accessed by phototherapy. These targets GB 2360461 discloses a flexible garment which uses a include, but are not limited to, the eye, wounds, nails, and conventional photodynamic therapy light source to produce internal parts of the body. Light can also be used in order to light which is then transmitted through optical fibres. As facilitate or Support disinfection of wounds, beverages, 40 Such light sources are heavy, the device is not ambulatory nutrition, for example. and is limited to hospital use. One effect of phototherapy is the stimulation of metabo U.S. Pat. No. 5,698,866 discloses a light source using lism in the mitochondria. Certain wavelengths of light over-driven inorganic LEDs. The resulting light output is not stimulate cytochrome c oxidase, an enzyme which is respon even. A heat-sinking mechanism is required, and the device sible for the production of the essential cellular energy in the 45 is suitable only for hospital treatment. form of adenosine triphosphate (ATP). ATP is required for WO 93/21842 discloses light sources using inorganic cellular energy transfer in order to drive thermodynamically LEDs. Although transportable, the device is not suitable for unfavoured biochemical reactions and as cellular energy ambulatory use by a patient at home and clinical treatment storage. ATP can also act as signal molecule in order to is envisaged. modulate other biochemical molecules (e.g. reactive oxygen 50 According to U.S. Pat. No. 6,283,956 LEDs are used for species and nitric oxide) that lead to ageing and cell death reduction, elimination or stimulation of hair growth. (oxidative stress). After phototherapy, the cells show an An essential prerequisite for the application of light in the increased metabolism, they communicate better and they fields mentioned above is the device. The commercial avail survive stressful conditions in a better way. able systems nowadays are mostly based on lasers. How Such principle can be applied for medicinal therapeutic 55 ever, theses systems are hospital based, i.e. stationary and cosmetic applications, such as wound healing, connec devices. In order to reduce costs and to increase convenience tive tissue repair, tissue repair, prevention of tissue death, as well as compliance a portable home-use technology is relief of inflammation, pain, acute injuries, chronic diseases, required. In fact, Some research has been devoted in this metabolic disorders, neurogenic pain and seasonal effect direction. disorders. 60 Rochester et al. disclosed in GB 24082092a flexible Another area of the application of light is the treatment of medical light Source including flexible light emitting diodes various cancers.